HOME >> MEDICINE >> NEWS
Light-weight heparin has heavy-weight results in heart attack treatment

DALLAS, Heart attack patients treated with the blood-thinner enoxaparin a low molecular weight heparin plus a clot dissolver were significantly less likely to die or have repeat heart attacks within 30 days compared to patients who received unfractionated heparin (UFH), according to a Rapid Track article in todays Circulation: Journal of the American Heart Association.

Patients in the study had what are known as ST-segment elevation myocardial infarctions, which are the most severe type of heart attack. We have very encouraging data but the evidence is not yet sufficient to say that enoxaparin should be standard treatment for severe heart attacks, says Elliott Antman, M.D., associate professor of medicine at Harvard Medical School and director of the coronary care unit of Brigham and Womens Hospital in Boston. However, the data suggest we should pursue a larger clinical trial.

Enoxaparin previously has been shown to be superior to unfractionated heparin (another blood thinner) for patients with milder heart attacks (non-ST segment elevation). It can be given as a simple injection, rather than the continuous infusion required with UFH, and it does not require frequent testing of the patients blood clotting status.

The researchers report their findings from the ENTIRE-TIMI 23 study. This international study involved 483 patients who presented with severe heart attacks at hospitals in the United States and Europe. Participants were randomly assigned either standard reperfusion with a full dose of the clot-dissolving drug tenecteplase (TNK) or combination therapy with abciximab and a half dose of TNK and either unfractionated heparin (UFH) or enoxaparin. Abciximab is a drug that helps keep blood platelets from sticking together to form clots.

The study was designed to evaluate enoxaparin as adjunctive treatment with various forms of reperfusion therapies (TNK, abciximab). To evaluate reperfusion (blood flow) researchers used the TIMI
'"/>

Contact: Carole Bullock
carole.bullock@heart.org
214-706-1279
American Heart Association
4-Mar-2002


Page: 1 2

Related medicine news :

1. The protective effects of heparin in preventing miscarriages in lupus patients
2. Newer formulation of heparin improves outcomes for suspected heart attack patients
3. New studies show mixed results on epilepsy drugs and birth defects
4. Study of obese diabetics explains why low-carb diets produce fast results
5. Sharing clinical trial results with participants may be beneficial
6. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
7. Similar results found in both older and younger patients undergoing weight-loss surgery
8. OHSU researcher says FDA could broaden access to results of clinical drug trials
9. Kinder, gentler procedure gives superior results for stem cell transplants
10. Good results with only one egg in in-vitro fertilization
11. Holiday feasting could sabotage liposuction results

Post Your Comments:
(Date:10/20/2014)... With a mere 19 days to November 4, ... fundraising stop at the  Law Offices of Dan ... debate last night with his opponent Gov. Rick Scott, ... seven minutes because Crist had an electric fan underneath ... one word: "weird." , Before touching on his well-known ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
(Date:10/20/2014)... CA (PRWEB) October 20, 2014 JZ ... expertise, nutritional coaching, corporate wellness programming, authorship, international lecturing ... is excited to announce the release of the JZ ... After many years of coaching thousands of individuals on ... tracking app that does not require calorie counting or ...
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 National Teen ... Chapter of the American Academy of Pediatrics (Ohio AAP, ... (NHTSA) in encouraging parents of teen drivers to talk to ... the road. , Motor vehicle crashes are the leading cause ... teen drivers involved in fatal crashes, and 859 (42%) of ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
(Date:10/20/2014)... N.J. , Oct. 20, 2014   ... Pharmaceutical Co., Ltd. ( Japan ), ... (FDA) granted Fast Track designation for TAS-102 (nonproprietary ... anticancer drug under investigation for the treatment of ... Company has initiated a rolling NDA submission to ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014 /PRNewswire/ ... Neuropathy Foundation (HNF), both philanthropies, announced today the ... candidates for the treatment of the rare disease ... BioPontis Alliance announced its alliance model earlier this ... first demonstration of a collaborative model where researchers ...
(Date:10/18/2014)... 2014  In a policy paper ... nation,s largest lesbian, gay, bisexual and transgender (LGBT) ... Truvada for Pre-Exposure Prophylaxis (PrEP). PrEP is any ... the spread of a disease or infection prior ... anti-HIV drug combination currently approved for PrEP, which ...
Breaking Medicine Technology:Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
Cached News: